Methotrexate News and Research

RSS
Methotrexate is an antimetabolite and antifolate agent with antineoplastic and immunosuppressant activities. Methotrexate binds to and inhibits the enzyme dihydrofolate reductase, resulting in inhibition of purine nucleotide and thymidylate synthesis and, subsequently, inhibition of DNA and RNA syntheses. Methotrexate also exhibits potent immunosuppressant activity although the mechanism(s) of actions is unclear.

Methotrexate is approved by the Food and Drug Administration (FDA) to be used by itself to treat the following types of gestational trophoblastic tumors, Chorioadenoma destruens, Choriocarcinoma, Hydatidiform mole. Methotrexate is also approved to be used alone or with other drugs to treat acute lymphoblastic leukemia (ALL) that has spread to the central nervous system (CNS) or to keep it from spreading there, and to treat the following, breast cancer, certain types of head and neck cancer, lung cancer, advanced non-Hodgkin lymphoma (NHL), advanced mycosis fungoides (a type of cutaneous T-cell lymphoma), osteosarcoma that has not spread to other parts of the body, following surgery to remove the primary tumor. Methotrexate is also approved to treat the following non-cancer conditions, rheumatoid arthritis, severe psoriasis.
Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Adjuvant chemotherapy not beneficial for patients with luminal A subtype of breast cancer

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

Novartis announces EC approval of Cosentyx for treatment of ankylosing spondylitis, psoriatic arthritis

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

Arthritis patients to be greater contributors to clinical guideline development

Arthritis patients to be greater contributors to clinical guideline development

Mylan announces U.S. launch of generic Fusilev for Injection

Mylan announces U.S. launch of generic Fusilev for Injection

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

CHMP recommends approval of Cosentyx in Europe to treat patients with AS and PsA, says Novartis

Roche to acquire biotechnology company, Adheron Therapeutics

Roche to acquire biotechnology company, Adheron Therapeutics

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

ACR releases two new publications to improve treatment of polymyalgia rheumatica, gout

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Hospira announces TGA approval of Inflectra (infliximab) for treatment of eight inflammatory conditions

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Turing Pharmaceuticals acquires rights to market Daraprim (pyrimethamine) in the U.S.

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

Steroid-refractory chronic GVHD trial results ‘overestimate’ treatment efficacy

AESKU.DIAGNOSTICS offers new early prognostic marker for RA

AESKU.DIAGNOSTICS offers new early prognostic marker for RA

Common arthritis drug could help to treat patients with blood cancers

Common arthritis drug could help to treat patients with blood cancers

Study: New test may help predict effectiveness of biologic drugs in RA patients

Study: New test may help predict effectiveness of biologic drugs in RA patients

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

MSD announces EC approval of SIMPONI (golimumab) for treatment of adult patients with nr-axial SpA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

Study shows that TNFi dose reduction strategy can help in optimal management of RA

Initial therapy with DMARDs improves disease activity, functional ability in patients with early RA

Initial therapy with DMARDs improves disease activity, functional ability in patients with early RA

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis

Time for a switch for patients with rheumatoid arthritis and ankylosing spondylitis